Clinical trialCLINICALTRIALSApr 1
Researchers are testing a combination of two cancer drugs called dabrafenib and trametinib in patients with rare tumors that have a specific genetic change called BRAF V600E. This is a phase IV study, which means the drugs have already been approved and doctors are gathering more information about how well they work. The study will include children (age 1 and up) and adults, and is currently looking for 40 patients to participate.
WHY IT MATTERSIf you have a rare solid tumor with a BRAF V600E mutation and your doctor has already recommended dabrafenib plus trametinib treatment, this trial offers an opportunity to participate in research that could help future patients while receiving the same treatment your doctor planned for you anyway.
Clinical trialCLINICALTRIALSApr 1
Researchers are looking for 88 people with Fragile X Syndrome or Creatine Transporter Deficiency to test a new imaging technology that can see how the brain works. Both of these are genetic conditions that affect how the brain develops and cause intellectual disability. This study might help doctors better understand and diagnose these conditions in the future.
WHY IT MATTERSThis trial is recruiting patients with two of the most common X-linked intellectual disability disorders and may provide a new diagnostic tool that could improve how these conditions are identified and monitored.
Clinical trialCLINICALTRIALSApr 1
This is a continuation study for patients who are already taking the cancer drugs dabrafenib and/or trametinib and have done well on them. If your doctor thinks you're still benefiting from these medications after your original trial ends, you may be able to keep taking them through this new study. The study is looking for about 100 patients with various types of cancer including melanoma, lung cancer, and brain tumors.
WHY IT MATTERSThis rollover study allows patients whose cancers are responding well to dabrafenib and/or trametinib to continue access to these drugs after their original trial ends, rather than losing treatment.
Clinical trialCLINICALTRIALSApr 1
Researchers are looking for 3,100 people to join a study about why patients don't take their medications as prescribed. The study will test a new approach to help people stick to their treatment plans, which could improve their health and reduce unnecessary hospital visits. About half of all patients don't take their medicines the right way, and this problem gets worse when treatment also requires lifestyle changes.
WHY IT MATTERSThis trial directly addresses medication non-adherence across multiple rare disease categories, meaning patients with rare conditions could benefit from proven strategies to better manage their treatments and health outcomes.
ResearchPUBMEDApr 1
Researchers tested whether people could get genetic testing (genome sequencing) without always needing to see a genetics specialist first. They studied 313 people of all ages who had unexplained symptoms and could refer themselves or be referred by any doctor. The study found that people who referred themselves were just as likely to get a diagnosis as those referred by specialists. This suggests a new way to make genetic testing available to more people while still having genetics experts review the results.
WHY IT MATTERSIf this hybrid model works, patients with rare diseases could access genome sequencing faster and more easily without waiting for a genetics specialist appointment, potentially shortening the diagnostic odyssey that many rare disease patients experience.
Clinical trialCLINICALTRIALSMar 31
Researchers are building a large international database to collect information and tissue samples from children, teens, and young adults with rare brain tumors. By gathering this data from 5,800 patients, scientists hope to better understand these uncommon cancers and develop better treatments. The study is currently looking for patients to participate.
WHY IT MATTERSThis registry directly addresses rare brain tumors like astroblastoma and BCOR ITD sarcoma that have limited research data—participating patients contribute to the only large-scale international effort to understand these specific tumor types.
ResearchCLINICALTRIALSMar 30
This study is looking for 2,800 people to help researchers understand how being a caregiver affects a person's health and stress levels over time. The study includes caregivers of people with rare diseases like Batten disease, Tay-Sachs disease, and other inherited metabolic disorders, as well as caregivers of people with undiagnosed diseases. By learning more about caregiver stress, researchers hope to find ways to better support the millions of unpaid family caregivers in the U.S.
WHY IT MATTERSIf you or a family member care for someone with a rare inherited metabolic disorder, Batten disease, Tay-Sachs, or an undiagnosed disease, this study directly addresses the health challenges caregivers face and could lead to better support resources.
ResearchCLINICALTRIALSMar 27
Researchers are looking for 63 participants to help them understand how DNA changes in babies before birth compare to DNA changes after birth. They want to collect DNA from amniotic fluid (the fluid around a baby in the womb) or from tissue samples after delivery to create a reference guide. This guide will help doctors better diagnose rare genetic diseases that start before birth.
WHY IT MATTERSThis trial could improve how doctors diagnose rare genetic diseases in fetuses and newborns by establishing what normal DNA patterns look like before birth, which is currently unknown.
Clinical trialCLINICALTRIALSMar 27
Researchers in France are recruiting 5,000 newborns to test a new way of screening for rare diseases using genome sequencing—a complete reading of a baby's DNA. Instead of the current blood spot tests that check for only a few dozen conditions, this study will see if reading a baby's entire genome can safely and effectively find many more rare genetic diseases at birth. This is one of the first major studies in Europe to test this approach.
WHY IT MATTERSThis trial could expand newborn screening in France to detect dozens of additional rare genetic diseases at birth, potentially allowing earlier treatment and better health outcomes for babies with conditions that currently go undiagnosed until symptoms appear.
Clinical trialCLINICALTRIALSMar 27
Researchers are looking for 1,000 people of any age who have a rare blood disorder called FPDMM, which is caused by a change in the RUNX1 gene. People with this condition may bleed easily and for longer than normal when injured. This study will help doctors better understand the disease, diagnose it more accurately, and find better ways to treat it.
WHY IT MATTERSThis is an active recruiting trial sponsored by the National Human Genome Research Institute seeking 1,000 participants with RUNX1-variant FPDMM — participation could directly advance understanding of diagnosis and treatment for this rare inherited bleeding disorder.
PolicyPUBMEDMar 26
France is creating a new type of healthcare worker called a Genomic Pathway Manager to help doctors order genetic tests for patients with rare diseases and cancer. These managers will make it easier for patients to get genetic testing by organizing the process and helping doctors understand when and how to use these tests. The goal is to make genetic testing available to more people across France starting in 2025.
WHY IT MATTERSIf you have a rare disease in France, this new system could help your doctor identify your condition faster through genetic testing, potentially leading to earlier diagnosis and treatment options.
PolicyPUBMEDMar 26
People with inherited metabolic diseases (IMDs) in Latin America struggle to get life-saving medicines that are more available in wealthy countries. This article looks at why these medicines are hard to find in places like Chile and suggests ways to make them more accessible to everyone who needs them, no matter where they live.
WHY IT MATTERSIf you or a family member has an inherited metabolic disease in Latin America, this research directly addresses the barriers preventing you from accessing treatments that patients in high-income countries can obtain.
ResearchPUBMEDMar 26
Researchers created DeepRare, a computer system that helps doctors diagnose rare diseases faster and more accurately. The system uses artificial intelligence to analyze patient information like symptoms, genetic test results, and medical history to suggest possible diagnoses. This could help patients avoid the long 'diagnostic odyssey' where they see many doctors over years before getting a correct diagnosis.
WHY IT MATTERSPatients with rare diseases spend an average of 5+ years seeking diagnosis with repeated misdiagnoses; DeepRare could dramatically shorten this timeline by providing doctors with AI-powered diagnostic support that integrates genetic and phenotype data.
ResearchPUBMEDMar 26
Researchers are developing a new way to make sure patients with Aicardi-Goutieres Syndrome (AGS) have a real voice in designing clinical trials for new treatments. AGS is a rare genetic disease that affects the brain and causes inflammation. This study creates a method to listen to what matters most to patients and families so that future drug trials measure the things that actually improve their lives.
WHY IT MATTERSAs new treatments for AGS move toward clinical trials, this research ensures that the outcomes being measured in those trials reflect what patients and families actually care about—not just what doctors think is important.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new gene therapy called SGT-212 for Friedreich's ataxia, a rare disease that affects how the body moves and coordinates. This is the first time this treatment is being tested in humans. The study will enroll 10 patients and follow them for about 5 years to see if the treatment is safe and works well.
WHY IT MATTERSThis is the first human trial of SGT-212 for Friedreich's ataxia, offering eligible patients access to a potentially disease-modifying gene therapy that addresses the underlying genetic cause rather than just managing symptoms.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for 1,500 people with inherited eye diseases caused by rare genetic changes to join a study. The study has two parts: first, they'll collect genetic information and eye health data from participants, and second, they'll follow some participants over time to understand how these eye diseases progress. This international study is now accepting new participants.
WHY IT MATTERSIf you have an inherited retinal disease with a rare genetic variant, enrolling in this registry could help researchers understand your condition better and speed up development of future treatments while contributing to a global database of genetic information.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new treatment for calciphylaxis, a serious condition where calcium builds up in blood vessels and skin tissue, causing painful sores. The treatment uses special cells from amniotic fluid (the fluid around a baby during pregnancy) to see if they can help heal the damage. This is an early-stage trial with a small group of 9 patients to check if the treatment is safe and works.
WHY IT MATTERSCalciphylaxis has very few treatment options and high mortality rates — this trial offers patients with chronic kidney disease a chance to access an experimental stem cell therapy that could reduce tissue damage and improve survival.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for pregnant women and breastfeeding mothers who have taken or are taking a medication called odevixibat to join a safety study. The study will track the health of these women and their babies to make sure the medication is safe to use during pregnancy and while breastfeeding. About 20 people will participate, and doctors will collect information from the mothers, babies, and healthcare providers involved in their care.
WHY IT MATTERSThis surveillance program is recruiting pregnant and lactating women exposed to odevixibat to establish safety data for a medication used in rare bile acid disorders, filling a critical gap in pregnancy and lactation safety information.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new cancer treatment called CART19 for children and young adults with specific types of blood cancer (B-ALL). The treatment uses the patient's own immune cells that are modified in a lab to fight cancer cells. This trial is looking for patients with rare, high-risk forms of this cancer, including some cases that have come back after previous treatment.
WHY IT MATTERSThis trial is actively recruiting children and young adults with hard-to-treat B-ALL subtypes (hypodiploid, t(17;19), KMT2A, and CNS relapse cases) — these patients have limited treatment options and this study offers access to an advanced cell therapy approach.
ResearchCLINICALTRIALSMar 26
Researchers at a hospital in France are collecting biological samples (like blood) from 1,000 patients with rare nervous system diseases that may be caused by the immune system attacking the body. These samples will help scientists find new ways to diagnose and treat these diseases by identifying special markers in the blood that show disease activity.
WHY IT MATTERSIf you have a rare autoimmune neurological disease, participating in this sample collection could help researchers discover new biomarkers and treatments specifically for conditions like yours.